2,618 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Purchased by Valence8 US LP

Valence8 US LP purchased a new stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,618 shares of the biotechnology company’s stock, valued at approximately $242,000.

Several other large investors have also recently added to or reduced their stakes in BPMC. Amalgamated Bank raised its stake in shares of Blueprint Medicines by 5.3% in the second quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock valued at $232,000 after purchasing an additional 109 shares in the last quarter. Van ECK Associates Corp raised its stake in shares of Blueprint Medicines by 13.3% in the 2nd quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 131 shares in the last quarter. EFG Asset Management North America Corp. lifted its holdings in shares of Blueprint Medicines by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 27,884 shares of the biotechnology company’s stock worth $3,008,000 after acquiring an additional 132 shares during the period. Pallas Capital Advisors LLC lifted its holdings in shares of Blueprint Medicines by 3.2% during the 3rd quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock worth $523,000 after acquiring an additional 176 shares during the period. Finally, US Bancorp DE boosted its position in shares of Blueprint Medicines by 5.2% during the 1st quarter. US Bancorp DE now owns 3,724 shares of the biotechnology company’s stock valued at $353,000 after acquiring an additional 183 shares in the last quarter.

Blueprint Medicines Stock Up 2.0 %

NASDAQ BPMC opened at $96.66 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. Blueprint Medicines Co. has a 52 week low of $65.68 and a 52 week high of $121.90. The stock has a market capitalization of $6.14 billion, a P/E ratio of -45.81 and a beta of 0.59. The stock has a fifty day moving average of $90.26 and a 200-day moving average of $98.69.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The firm had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. During the same period last year, the company earned ($2.20) earnings per share. The company’s revenue was up 126.5% on a year-over-year basis. On average, equities research analysts forecast that Blueprint Medicines Co. will post -3.66 EPS for the current year.

Insider Buying and Selling

In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the sale, the insider now owns 69,070 shares of the company’s stock, valued at approximately $6,169,332.40. The trade was a 5.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.21% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. JMP Securities restated a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a research note on Monday. Needham & Company LLC restated a “buy” rating and set a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, November 15th. Guggenheim upped their price target on Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Wells Fargo & Company dropped their price objective on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Finally, Barclays boosted their target price on shares of Blueprint Medicines from $75.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, July 29th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $122.11.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.